Neuronascent discovers and develops therapeutics for down syndrome, alzheimer’s, parkinson’s disease and neurodegenerative disorder... Read more
Neuronascent discovers and develops therapeutics for down syndrome, alzheimer’s, parkinson’s disease and neurodegenerative disorder... Read more
News
Aug 13, 2025
GlobalNewswire
Press Release: NeuroNascent : Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions
Aug 22, 2023
BioSpace
NeuroNascent: Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer's Disease
Jun 28, 2023
Benzinga
NeuroNascent: Neuronascent to Present New Parkinson's Model Data at AAIC 2023 for the Alzheimer's Disease Investigational Therapy, NNI-362
Apr 19, 2023
Pharamceutical Technology
NeuroNascent: Neuronascent plans Phase II Parkinson's disease trial with neurorestorative drug
Nov 08, 2022
Benzinga
NeuroNascent: Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer's Disease
Jun 01, 2022
FirstWord Pharma
NeuroNascent: Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
May 24, 2022
FirstWord Pharma
NeuroNascent: Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
Mar 30, 2022
FirstWord Pharma
NeuroNascent: Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer's Disease
Sep 29, 2021
Markets Insider
NeuroNascent: Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease
Jan 20, 2021
MarketScreener
NeuroNascent: Neuronascent Announces Publication of Pre-clinical Results of Alzheimer's Disease Clinical Candidate, NNI-362 in SCR&T Journal
NeuroNascent Competitors
1
2
3
4
5
6
7
8
9
10